Kera Capital Partners Inc. Acquires Shares of 26,849 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Kera Capital Partners Inc. bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 26,849 shares of the company’s stock, valued at approximately $218,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Huntington National Bank increased its holdings in Phathom Pharmaceuticals by 62.2% in the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock valued at $27,000 after acquiring an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Phathom Pharmaceuticals by 41.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after purchasing an additional 722 shares during the last quarter. US Bancorp DE lifted its position in shares of Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after buying an additional 1,166 shares in the last quarter. Quest Partners LLC bought a new position in Phathom Pharmaceuticals during the third quarter valued at approximately $197,000. Finally, Intech Investment Management LLC purchased a new position in Phathom Pharmaceuticals during the 3rd quarter valued at approximately $207,000. Institutional investors own 99.01% of the company’s stock.

Insider Buying and Selling

In other news, Director Frank Karbe acquired 12,500 shares of the business’s stock in a transaction on Friday, December 13th. The shares were acquired at an average price of $7.93 per share, for a total transaction of $99,125.00. Following the completion of the transaction, the director now directly owns 57,000 shares of the company’s stock, valued at approximately $452,010. The trade was a 28.09 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 24.10% of the stock is owned by corporate insiders.

Phathom Pharmaceuticals Stock Performance

Shares of Phathom Pharmaceuticals stock opened at $6.96 on Monday. The stock has a market cap of $475.92 million, a price-to-earnings ratio of -1.22 and a beta of 0.56. The stock has a 50 day moving average price of $8.31 and a 200-day moving average price of $12.61. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $19.71.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.